TGFB1 and pulmonary fibrosis: However, therapeutic targeting of TGF-β1 or its receptors did not slow progression of nephropathy in clinical trials [12], and also failed to reduce pulmonary fibrosis in a mouse model, while exacerbating inflammation associated with disease progression [11].